KRAS and acinar cell carcinoma: 61 (52.7%) patients were male; 25 (19.4%) patients were above age of 65; 57 (44.2%) patients were smokers; 92 (71.3%) patients were diagnosed as stage I/II; 41 (31.8%) cancer were characterized as acinar adenocarcinoma; high PD-L1 expression in 53 (41.1%) patients; high VEGFA expression in 65 (50.4%); 56 (43.4%) patients had EGFR mutations and 17 (12.2%) patients had other mutations including KRAS mutations and ALK mutations; 29 (38.2%) cases were in VEGFA-&PD-L1- group, 47 (61.8%) were in VEGFA+&PD-L1- group, 35 (66.0%) were in VEGFA-&PD-L1+ group and 18 (34.0%) were in VEGFA+&PD-L1+ group.